Company intelligence / Profile preview

CoMentis, Inc.

South San Francisco, California, United Statescomentis.co.uk ↗

Ownership: Private
Employees: ~24
Development stage: Phase 1

Overview

CoMentis has several programs in its pipeline, with APN-1125 for Schizophrenia being suspended, Mecamylamine Hydrochloride and ATG-002 being discontinued, and DMXB-Anabaseine and GRL-8234 pending further development

Therapeutic areas: OphthalmologyEndocrinologyPsychiatryNeurology
Modalities: Small molecules
Industry: Biotech

Drug pipeline

6 assets

dmxb-a

5 more assets in the full pipeline.

Request access →

Beyond the preview

Go deeper on CoMentis, Inc..

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on CoMentis, Inc..

Explore the full profile